Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
A new retrospective study examines the effect of bisphosphonates on COVID-19 outcomes.
Prostate cancer is the most common type of cancer among men in the United States aside from skin cancer, according to the Centers for Disease Control and Prevention.
A landmark study by researchers from the SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute, part of the National Institutes of Health, has found that 2.8 percent of patients on average develop osteonecrosis of the jaw, or ONJ, within three years of starting a common treatment for cancer that has spread to the bone.
Hutchinson-Gilford Progeria Syndrome (HGPS) is a fatal condition that is especially prevalent in the skin, cardiovascular and the musculoskeletal systems. There exists a wide gap between existing knowledge of the disease and a potential treatment or cure.
Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich.
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
Researchers in China have discovered that an enzyme called UGT8 drives the progression of basal-like breast cancer, an aggressive form of the disease that is largely untreatable.
A possible 'first-line' treatment for a rare bone loss disease has been identified by a research team led by Tohoku University in Japan. The research findings, published in the journal Molecular Cell, could also provide insight into treating age-related osteoporosis.
Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
An Australian-led research team has demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma.
Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.
Osteoporosis is preventable and treatable, but only a small proportion of people at risk for fractures are evaluated and treated, according to new osteoporosis guidelines written by an expert panel headed by Loyola Medicine endocrinologist Pauline M. Camacho, MD, FACE.
A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV-infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).
The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.
Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.
Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF).
Women with metastatic breast cancer to the bone may be able to receive bisphosphonates, the bone-targeting class of drugs like zoledronic acid, less often after the first year of monthly administration.
A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.